Approach to the Patient with Subclinical Cushing’s Syndrome

Author(s): Miomira Ivović, Ljiljana V. Marina*, Antoan S. Šojat, Milina Tančić-Gajić, Zorana Arizanović, Aleksandra Kendereški, Svetlana Vujović

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 43 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

A growing number of patients with adrenal incidentalomas and subclinical Cushing’s syndrome (SCS) led to an increasing number of different guidelines, and diagnostic and treatment recommendations. Excess cortisol secretion in patients with SCS is associated with several comorbidities, such as hypertension, dyslipidemia, type 2 diabetes mellitus, and obesity, which in the long-term increase mortality of these patients. Subtle cortisol secretion affects bone health, quality of life and causes depression, but due to the unapparent clinical features, patients with SCS are often at risk between over and under treatment. This narrative review aimed to summarize the latest recommendations on the approach to the patient with subclinical Cushing’s syndrome.

Keywords: Subclinical Cushing's syndrome, adrenal incidentaloma, possible autonomous cortisol secretion, mild autonomous cortisol secretion, mild autonomous cortisol excess, adrenal tumor, non-functional adrenal incidentaloma.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 43
Year: 2020
Published on: 22 December, 2020
Page: [5584 - 5590]
Pages: 7
DOI: 10.2174/1381612826666200813134328
Price: $65

Article Metrics

PDF: 17